<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583088</url>
  </required_header>
  <id_info>
    <org_study_id>AOM11046</org_study_id>
    <nct_id>NCT01583088</nct_id>
  </id_info>
  <brief_title>Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation</brief_title>
  <acronym>RespiStimALS</acronym>
  <official_title>Can Diaphragm Pacing Delay Non Invasive Ventilation in Amyotrophic Lateral Sclerosis ? a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARSla (Association pour la recherche sur la SLA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation Thierry Latran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALS is is characterized by a progressive degeneration of motor neurons, leading to&#xD;
      progressive weakness of muscles, including respiratory muscles, the diaphragm. Although&#xD;
      specific therapy is lacking, correct respiratory therapy improves quality of life and&#xD;
      increases survival. Substituting the failing respiratory muscles by non invasive mechanical&#xD;
      ventilatory assistance (NIV) is the current standard of care. Intradiaphragmatic phrenic&#xD;
      nerve stimulation is a new treatment and has been the object of a preliminary international&#xD;
      proof-of-concept multicenter trial. This trial suggests that the intradiaphragmatic phrenic&#xD;
      nerve stimulation slows down the rate of decline of the diaphragm. Our new hypothesis is that&#xD;
      phrenic stimulation induces diaphragm conditioning and can delay the need for mechanical&#xD;
      ventilation in ALS patients. We will study, during 24 months, 2 groups of 37 patients at the&#xD;
      beginning of the respiratory dysfunction, using a intradiaphragmatic phrenic nerve&#xD;
      stimulation in one group and a sham stimulation in the other group. Although, all the&#xD;
      patients will be implanted, thus, at the end of the study, all the patients will receive&#xD;
      effective stimulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ALS is is characterized by a progressive degeneration of upper and lower motor neurons,&#xD;
      leading to progressive weakness of bulbar, limb, thoracic and abdominal muscles. Although&#xD;
      specific therapy is lacking, correct respiratory therapy improves quality of life and&#xD;
      increases survival. Substituting the failing respiratory muscles by non invasive mechanical&#xD;
      ventilatory assistance (NIV) is the current standard of care.Intradiaphragmatic phrenic nerve&#xD;
      stimulation, has been the object of a preliminary proof-of-concept multicenter trial&#xD;
      (ClinicalTrials.gov NCT00420719).&#xD;
&#xD;
      Aim of the study : To test the hypothesis that phrenic stimulation induced diaphragm&#xD;
      conditioning can delay the need for mechanical ventilation in ALS patients.&#xD;
&#xD;
      Methods : It is a double blind randomized study. Patients presenting with early signs of&#xD;
      respiratory impairment (VC between 85 and 60%), but with a preserved electromyographic&#xD;
      response of the diaphragm to phrenic nerve stimulation, will be randomized in 2 groups. All&#xD;
      the patients will be treated according to current standards of care. They will all be&#xD;
      implanted with a phrenic stimulator, and then randomized between actual diaphragm&#xD;
      conditioning and sham stimulation.&#xD;
&#xD;
      Respiratory function will be followed up on a trimonthly basis, with polysomnography and&#xD;
      diaphragmatic EMG biannually. NIV (+ stimulation for both groups), will be initiated&#xD;
      according to currently recommended criteria of hypoventilation.&#xD;
&#xD;
      The main outcome of the study will be the number of months between the phrenic nerve&#xD;
      implantation and the introduction of NIV. Currently available data, showing that diaphragm&#xD;
      pacing can increase the number of patients without NIV at 2 years from 2,5% to 15% of the&#xD;
      patients, requires the enrollment of 37 patients in each group. Secondary end-points will&#xD;
      include i.Survival ii. Effects on sleep iii. Quality of life and daily activities&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    in the absence of benefits and because of a statistically significant excess mortality in the&#xD;
    group of patients receiving active stimulation.&#xD;
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without NIV 2 years after the phrenic nerve implantation.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>global survival from onset disease</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effects on sleep</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and daily activities</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>phenic nerve stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>effective phenic nerve stimulation NeurX™ (Synapse Biomedical)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham phenic nerve stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>phenique nerve stimulation NeurX™ (Synapse Biomedical)</intervention_name>
    <description>phenique nerve stimulation NeurX™ (Synapse Biomedical)</description>
    <arm_group_label>phenic nerve stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham phrenic nerve stimulation</intervention_name>
    <description>sham phenic nerve stimulation</description>
    <arm_group_label>sham</arm_group_label>
    <other_name>sham phenic nerve stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis is laboratory-supported probable, probable, or definite according to the&#xD;
             World Federation of Neurology El Escorial criteria&#xD;
&#xD;
          -  Forced Vital Capacity (FVC) from 80 - 60% of predicted values at enrollment&#xD;
&#xD;
          -  Bilateral phrenic nerve function acceptable as demonstrated by bilateral diaphragm EMG&#xD;
             recordings and nerve conduction times without axonal lesion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active cardiovascular disease that would increase the risk of general anesthesia.&#xD;
             (FEVG&lt;60%)&#xD;
&#xD;
          -  Underlying pulmonary diseases that were present prior to ALS that would effect&#xD;
             pulmonary tests independent of ALS, in particular COPD with FEV1&lt;30%&#xD;
&#xD;
          -  Pre-existing implanted electrical device such as a pacemaker or cardiac defibrillator&#xD;
&#xD;
          -  respiratory infection or decompensation in the last 30 days&#xD;
&#xD;
          -  Marked obesity affecting suitability for surgery&#xD;
&#xD;
          -  Significant scoliosis or chest deformity affecting suitability for surgery&#xD;
&#xD;
          -  Pre-existing diaphragm abnormality such as a hiatal hernia or paraesophageal hernia&#xD;
&#xD;
          -  Patient on NIV, CPAP or Oxygen for a reason other than ALS&#xD;
&#xD;
          -  Criteria for NIV (VC&lt;50% of predicted values and/or Pi max and SNIP&lt;60% of predicted&#xD;
             values; and/or nocturnal desaturations without SAOS and/or PaCO2&gt;45 mm d'Hg)&#xD;
&#xD;
          -  Supine VC&lt;50% of predicted values&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gonzalez-Bermejo Jesus, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APHP, GH Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 20, 2012</study_first_submitted>
  <study_first_submitted_qc>April 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2012</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic lateral sclerosis,</keyword>
  <keyword>Diaphragm</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Phrenic nerve stimulation</keyword>
  <keyword>Respiratory insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

